Together, these findings suggest that a suppressive intervention targeting DNMT1 is most likely to reduce the adverse toxicity to maintain normal glucose balance in the context of PI3K inhibition-induced hyperglycemia, further enhancing the effectiveness of anticancer treatments. Here, PIK3CD is linked to Hyperglycemia.